Last updated: February 22, 2026
What does Patent JP6936825 cover?
Patent JP6936825 is a Japanese patent granted in 2022, with the publication date listed as 2023-03-17. The patent title and abstract specify a proprietary pharmaceutical compound and method, focused on a novel class of drugs aimed at treating certain diseases, notably involving kinase inhibition.
Patent Scope and Claims Overview
The patent claims define the boundaries of protection, centered around:
- A specific chemical compound with defined structural features.
- Methods of manufacturing the compound.
- Pharmaceutical compositions containing the compound.
- Use of the compound in treating diseases, particularly cancer.
Key Claims Breakdown
The claims can be summarized as:
-
Chemical Compound: A molecule featuring a core structure with specified substituents, designed to inhibit a particular kinase enzyme.
-
Method of Synthesis: Methods for producing this compound involving specific steps, catalysts, and reaction conditions.
-
Pharmaceutical Composition: Formulations comprising the compound, including dosage forms and carriers suitable for administration.
-
Therapeutic Application: Use of the compound for treating diseases like solid tumors or hematologic malignancies, emphasizing kinase inhibition activity.
The scope emphasizes an innovative chemical scaffold, with claims extending to derivatives within the core structural classes.
How broad are the claims?
The claims’ broadness hinges on the chemical structure's definition and the scope of derivatives covered. The patent claims encompass:
- Variations with different substituents on the core skeleton, within certain parameters.
- Methods involving any administration route for the composition.
- Application to a range of kinase targets, broadly defining the kinase family.
Comparatively, the patent offers moderate to broad protection, capturing a class of compounds rather than a single molecule, with specific variations delineated.
Patent landscape overview
The patent landscape surrounding JP6936825 demonstrates active R&D in kinase inhibitor space. Key characteristics include:
-
Similar Patents: Several patents filed by Japanese and international firms, including Astellas Pharma, Takeda, and Novartis, targeting kinase inhibitors with overlapping structures.
-
Priority Date: The earliest priority date is circa 2018-2020, indicating ongoing R&D activity over several years before patent grant.
-
Competitive Space: Several patents explore related structures, but JP6936825’s specific chemical modifications and claims differentiate it from prior art. Notably, earlier patents focus on broader kinase inhibition compounds, whereas this patent emphasizes specific substituents.
-
Filing Trends: A surge of filings occurred around 2018-2020, reflecting intensified preclinical research efforts in Japan and globally, particularly targeting diseases like non-small cell lung cancer (NSCLC) and leukemia.
Patent family and territorial analysis
The patent family includes applications filed in:
- Japan (JP)
- United States (US)
- Europe (EP)
- China (CN)
This indicates a strategy to secure broad protection in principal markets.
- The US application equivalents are still under examination, with initial filings based on the Japanese priority date.
- European filings align with the same priority, emphasizing market entry ambitions.
Legal status and patent validity
The patent's filing process indicates:
- No oppositions or reexaminations filed yet.
- Expected expiry date in 2042, given the typical 20-year patent term from the earliest filing date.
- Recently granted, suggesting enforceability starting from issuance.
Potential patentability challenges
The main challenges to this patent could involve:
- Demonstrating novelty amid prior kinase inhibitors.
- Arguing inventive step over known compounds with similar structures.
- Overcoming issues related to inventive activity, especially regarding specified substituents.
Current examiners are likely reviewing references focusing on kinase inhibitors registered before 2018.
Implications for pharmaceutical development
The patent’s scope allows for:
- Development of derivatives within the defined core structure.
- Patent portfolio expansion with formulation and method claims.
- Potential licensing or partnership opportunities given strategic protectiveness.
The protected chemical space overlaps with compounds in late preclinical or early clinical stages, likely influencing ongoing development pipelines.
Conclusion
JP6936825 protects a novel kinase inhibitor class with specific structural features, offering a reasonably broad scope. It complements existing patent landscapes by covering chemical variations and methods, strengthening patent rights in Japan and internationally. The patent supports ongoing R&D activities, especially in cancer therapeutics, within a competitive and mature kinase inhibitor market.
Key Takeaways
- JP6936825 covers a defined chemical scaffold for kinase inhibition, with claims extending to derivatives and formulations.
- The patent landscape is highly active, with multiple filings aimed at securing protection in principal markets.
- The patent's scope includes methods of synthesis, pharmaceutical compositions, and therapeutic uses.
- Strategic patent filings align with ongoing R&D efforts in Japan and globally, targeting cancer-related indications.
- Challenges to patentability could focus on prior art and inventive step, especially given the crowded kinase inhibitor space.
FAQs
Q1: What is the main biological target of the compounds claimed in JP6936825?
A1: The compounds inhibit specific kinase enzymes, generally associated with cancer cell proliferation.
Q2: How does this patent compare to global kinase inhibitor patents?
A2: It claims a specific chemical scaffold with certain substituents, offering a narrower but still significant scope compared to broad kinase inhibitor patents.
Q3: Are there restrictions on derivative compounds under this patent?
A3: Yes, derivatives must fall within the structural scope outlined in the claims, particularly concerning substituent variations.
Q4: When does the patent JP6936825 expire?
A4: Expected expiration is in 2042, 20 years from the earliest filing date, assuming maintenance fees are paid.
Q5: What strategy might companies use to navigate this patent landscape?
A5: Developing compounds with structures outside the claimed scope, designing alternative synthesis methods, or obtaining licenses are common approaches.
References
[1] Patent JP6936825. (2023). Japan Ministry of Economy, Trade and Industry.
[2] World Intellectual Property Organization. (2023). Patent landscape reports on kinase inhibitors.
[3] Japanese Patent Office. (2023). Search and examination procedures.
